2-甲基噻唑-4-甲酸乙酯 | 6436-59-5

• 物质功能分类: 香精与香料 - 合成香料 - 内酯和含氧杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-甲基噻唑-4-甲酸乙酯
• 中文别名: 2-甲基-1,3-噻唑-4-羧酸乙酯；2-甲基噻唑-4-甲酸甲酯
• 英文名称: ethyl 2-methylthiazole-4-carboxylate
• 英文别名: 2-methylthiazole-4-carboxylic acid ethyl ester；ethyl 2-methyl-1,3-thiazole-4-carboxylate；2-methyl-4-thiazolecarboxylic acid ethyl ester
• CAS: 6436-59-5
• 化学式: C₇H₉NO₂S
• mdl: MFCD00156148
• 分子量: 171.22
• InChiKey: QWWPUBQHZFHZSF-UHFFFAOYSA-N

物化性质

• 熔点：
  54-58 °C
• 沸点：
  242.1±13.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934100090
• 安全说明：
  S26,S37
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  冷藏保存。

SDS

Name:	Ethyl 2-methyl-1 3-thiazole-4-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	6436-59-5

Section 1 - Chemical Product MSDS Name:Ethyl 2-methyl-1 3-thiazole-4-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6436-59-5	Ethyl 2-methyl-1,3-thiazole-4-carboxyl	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6436-59-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow - brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 54 - 56 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H9NO2S
Molecular Weight: 171

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6436-59-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 2-methyl-1,3-thiazole-4-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 6436-59-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6436-59-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6436-59-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基噻唑-4-甲酸乙酯 在 吡啶 、 lithium aluminium tetrahydride 、 正丁基锂 、 草酰氯 、 硝基甲烷 、 丁硫醇 、 四溴化碳 、 dimethyl sulfide borane 、 (1R)-(+)-pinene 、 2,4,6-三氯苯甲酰氯 、 ammonium chloride 、 氟化氢吡啶 、 溶剂黄146 、 二甲基亚砜 、 三乙胺 、 二异丙胺 、 间氯过氧苯甲酸 、 三苯基膦 、 magnesium bromide 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 乙醚 、 正己烷 、 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 62.33h， 生成 埃博霉素B
  参考文献：
  名称：

  上表素B和D的总合成

  摘要：

  描述了收敛的全合成的埃坡霉素B（2）和D（4）。关键步骤是通过Normant偶联在C12-C13上建立所需的（Z）-立体化学，Wadsworth-Emmons甲基酮28与膦酸酯8的烯键化，醛5与醛酸与酮酸衍生物的烯酸酯的非对映选择性醛醇缩合以形成C6-C7键，酸52的选择性脱保护和大内酯化。

  DOI：

  10.1021/jo048742o
• 作为产物：
  描述：

  2-acetylamino-3-oxo-propionic acid ethyl ester 在 劳森试剂 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 生成 2-甲基噻唑-4-甲酸乙酯
  参考文献：
  名称：

  使用C-甲酰化策略从常见的无环前体合成咪唑，恶唑，噻唑和2,5-二羧酸吡嗪二乙酯的取代酯

  摘要：

  报道了一种通过甘氨酸乙酯盐酸盐的C-甲酰化反应合成咪唑，恶唑，噻唑和吡嗪-2,5-二羧酸二乙酯的取代酯的新颖合成途径。该方法简单，稳健，并且可以在一个或两个步骤中从常见的无环前体中很好地获得不同杂环酯的收率，并且适合大规模合成。

  DOI：

  10.1016/j.tetlet.2014.03.039

文献信息

• [EN] IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION<br/>[FR] DÉRIVÉS D'IMIDAZOTHIADIAZOLE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DU RÉCEPTEUR 4 ACTIVÉ PAR UNE PROTÉASE (PAR4) POUR LE TRAITEMENT DE L'AGRÉGATION PLAQUETTAIRE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013163279A1

  公开（公告）日：2013-10-31

  The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

  本发明提供了式I的噻唑化合物，其中W、Y、R0、R2、R4、R5、R6、R7、X1、X2、X3和X4如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药酯或溶剂化合物形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。
• [EN] SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 2-AZABICYCLO[3.1.1]HEPTANE ET DE 2-AZABICYCLO[3.2.1]OCTANE SUBSTITUÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
  申请人：CHRONOS THERAPEUTICS LTD

  公开号：WO2019043407A1

  公开（公告）日：2019-03-07

  There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

  提供一种化合物，其化学式为（I），其中L1至L3，R1至R4，X，A和B的含义如描述中所给，并且其药学上可接受的盐、溶剂合物和前药，这些化合物可用作促进睡眠素-1和促进睡眠素-2受体的拮抗剂或作为促进睡眠素-1受体的选择性拮抗剂，因此，特别适用于治疗或预防物质依赖、成瘾、焦虑障碍、恐慌障碍、暴饮暴食、强迫障碍、冲动控制障碍、认知障碍和阿尔茨海默病等疾病。
• Synthesis and biological evaluation of 2,4,5-trisubstituted thiazoles as antituberculosis agents effective against drug-resistant tuberculosis
  作者：Uttam B. Karale、Vagolu Siva Krishna、E. Vamshi Krishna、Amit S. Choudhari、Manjulika Shukla、Vikas R. Gaikwad、B. Mahizhaveni、Sidharth Chopra、Sunil Misra、Dhiman Sarkar、Dharmarajan Sriram、V.N. Azger Dusthackeer、Haridas B. Rode

  DOI：10.1016/j.ejmech.2019.05.082

  日期：2019.9

  The dormant and resistant form of Mycobacterium tuberculosis presents a challenge in developing new anti-tubercular drugs. Herein, we report the synthesis and evaluation of trisubstituted thiazoles as antituberculosis agents. The SAR study has identified a requirement of hydrophobic substituent at C2, ester functionality at C4, and various groups with hydrogen bond acceptor character at C5 of thiazole

  结核分枝杆菌的休眠和耐药形式在开发新的抗结核药物方面提出了挑战。在此，我们报道了三取代噻唑类作为抗结核剂的合成和评价。SAR研究已经确定了噻唑支架在C2处具有疏水取代基，在C4处具有酯官能度以及在C5处具有氢键受体特性的各种基团的需求。这导致鉴定出13h和13p为先导化合物。这些化合物选择性地抑制了休眠的结核分枝杆菌H37Ra菌株和结核分枝杆菌H37Rv。重要的是，13h和13p对CHO细胞无毒。这13p显示出对耐多药结核病分离株的活性。
• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。
• PAR4 AGONIST PEPTIDES
  申请人：Bristol-Myers Squibb Company

  公开号：US20130289238A1

  公开（公告）日：2013-10-31

  The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

  本发明提供PAR4激动肽。这些肽对于开发强大的PAR4受体测定方法非常有用。